Abstract:Background Invasive fungal infection (IFI) is a common and fatal complication in neutropenic patients with hematological malignancy. Empirical antifungal therapy is widely used in practice due to the difficulty of pathogens determination and illness of the hosts. The aim of this study was to evaluate the efficacy and safety of itraconazole as empirical antifungal therapy for persistent fever in neutropenic patients with hematologic malignancies.Methods Two hundred and seventy-four patients with hematologic malignancies who had suspected fungal infections were enrolled in 18 centers across China between April 2008 and April 2009. Empirical antifungal therapy with intravenous itraconazole 200 mg twice daily was given for the first two days, followed by 200 mg once daily for the next 12 days. Oral itraconazole solution was sequential for follow-up therapy if necessary. Five composite end points were evaluated for the response, which was more restrictive and adopted for the first time in such study in China.Results The intent-to-treat analysis included data from 274 patients (full analysis set, FAS), of whom 248 were included as the per-protocol population (PPS). As the composite end point of five indices was concerned, the overall response rate was 43.4%. Seperately, defervescence was achieved in 90% of patients in which 55.5% occured during neutropenia. The mean time to defervescence was 2.71 days. Absence of breakthrough IFI during drug administration or within the first 7 days after study completion was observed in 71.5% of patients. Fifty-five point five percent patients with IFI at baseline was successfully treated. Ninety point five percent patients survived for at least 7 days after completing the study. PPS analysis revealed that the duration of neutropenia >= 10 days was a statistically significant negative predictor for the response. The withdrawal rate due to drug-related toxicity or lack of efficacy was 11.0%. The incidence of adverse events was 22.6%, in which 11.6% was study drug related. The most frequent adverse events were mild to moderate liver toxicity.Conclusion ltraconazole shows desirable efficacy and safety as empirical antifungal therapy for febrile neutropenic patients with hematologic malignancies. Chin Med J 2011;124(22):3670-3675

Safety analysis of itraconazole clinical application

In Vitro Interaction of Itraconazole with Amphotericin B, Caspofungin, and Terbinafine Against Clinical Isolates of Trichosporon asahii

Population Pharmacokinetics of Isavuconazole in Adult: A Systematic Review

Analysis of 84 Cases of Adverse Reactions Induced by Voriconazole

Efficacy and Safety of Itraconazole As Empirical Antifungal Therapy in Febrile Neutropenic Patients with Hematologic Malignancies: an Open-Lable, Multicenter, Observational Trial in A Chinese Cohort

Efficacy and Safety of Itraconazole on Invasive Fungal Infections in 66 Patients with Malignant Hematological Diseases

A Multicenter, Open-Label Study of Posaconazole Oral Suspension in the Treatment of Invasive Fungal Infections in Patients Refractory to or Intolerant of First-Line Therapy.

Differential Effects of Ketoconazole, Fluconazole, and Itraconazole on the Pharmacokinetics of Pyrotinib in Vitro and in Vivo

Clinical study on the efficacy and safety of intravenous itraconazole infusion for the treatment of invasive fungal infection in China

Trough Concentration of Itraconazole and Its Relationship with Efficacy and Safety: a Systematic Review and Meta-Analysis

[Hepatic Safety of Itraconazole Intravenous Solution in Treatment of Invasive Fungal Infection].

Progress in Clinical Research of Itraconazole in the Treatment of Vulvovaginal Candidiasis

A Clinical Trial of Intravenous Itraconazole Followed by Itraconazole Capsule in the Treatment of 25 Cases of Systemic Fungal Infection

Genetic variations of CYP3A4 on the metabolism of itraconazole in vitro

Study on efficacy and safety of itraconazole in treatment of pulmonary fungal infections in elderly patients

Evaluating cardiac disorders associated with triazole antifungal agents based on the US Food and Drug Administration Adverse Event reporting system database

A Retrospective Study of Efficacy and Safety of Itraconazole for Treatment of Invasive Fungal Infection in Hematologic Diseases

[Efficacy and Safety of Intravenous Itraconazole in Different Antifungal Strategies for Patients Undergoing Intensive Chemotherapy or Hematopoietic Stem Cell Transplantation].

Meta-analysis of Therapeutic Efficacy of Itraconazole Against Invasive Fungal Infection in Hematology Patients

Effect of itraconazole on the activity of CYP450 1A2 and CYP450 3A4 of health adult human primary hepatocytes microsome

SUBA-itraconazole in the treatment of systemic fungal infections